A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

ClinicalTrials.gov ID: NCT00697203

Public ClinicalTrials.gov record NCT00697203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind Study of the Effect of RO4607381 in Combination With Pravastatin on HDL-cholesterol (HDL-C) Levels in Patients With Low or Average HDL-C Levels

Study identification

NCT ID: NCT00697203
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 292 participants

Conditions and interventions

Conditions

Dyslipidemia

Interventions

Placebo Drug
Pravastatin Drug
Dalcetrapib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2005
Primary completion: Apr 30, 2006
Completion: Apr 30, 2006
Last update posted: Jan 1, 2020

2005 – 2006

United States locations

U.S. sites: 33
U.S. states: 22
U.S. cities: 33

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	36608	—
Not listed	Scottsdale	Arizona	85251	—
Not listed	Newark	Delaware	19713	—
Not listed	Miami	Florida	33137	—
Not listed	Chicago	Illinois	60610-4319	—
Not listed	Evansville	Indiana	47714	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Iowa City	Iowa	52242	—
Not listed	Overland Park	Kansas	66215	—
Not listed	Wichita	Kansas	67207	—
Not listed	Louisville	Kentucky	40213	—
Not listed	Chalmette	Louisiana	70043	—
Not listed	Slidell	Louisiana	70458	—
Not listed	Auburn	Maine	04210	—
Not listed	Scarborough	Maine	04074	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Bethesda	Maryland	20817	—
Not listed	Towson	Maryland	21204	—
Not listed	St Louis	Missouri	63110	—
Not listed	Concord	New Hampshire	03301	—
Not listed	Charlotte	North Carolina	28209	—
Not listed	Statesville	North Carolina	28677	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Cincinnati	Ohio	45212	—
Not listed	Springdale	Ohio	45246	—
Not listed	Oklahoma City	Oklahoma	73103	—
Not listed	Philadelphia	Pennsylvania	19107	—
Not listed	Warminster	Pennsylvania	18974	—
Not listed	Fort Worth	Texas	76107	—
Not listed	Houston	Texas	77030	—
Not listed	Richmond	Virginia	23294	—
Not listed	Seattle	Washington	98104	—
Not listed	Madison	Wisconsin	53719	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00697203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 1, 2020 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00697203 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →